1. Home
  2. XELB vs IKT Comparison

XELB vs IKT Comparison

Compare XELB & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Brands Inc.

XELB

Xcel Brands Inc.

N/A

Current Price

$0.89

Market Cap

8.4M

Sector

Miscellaneous

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$2.31

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XELB
IKT
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
220.5M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
XELB
IKT
Price
$0.89
$2.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$3.00
$5.00
AVG Volume (30 Days)
104.7K
370.8K
Earning Date
04-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
48.37
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.33
52 Week High
$2.66
$2.61

Technical Indicators

Market Signals
Indicator
XELB
IKT
Relative Strength Index (RSI) 43.43 44.92
Support Level $0.63 $2.29
Resistance Level $1.16 $2.56
Average True Range (ATR) 0.09 0.10
MACD 0.02 -0.02
Stochastic Oscillator 20.65 16.08

Price Performance

Historical Comparison
XELB
IKT

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: